[
  {
    "ts": null,
    "headline": "Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack",
    "summary": "The Investment Committee debate the latest Calls of the Day.",
    "url": "https://finnhub.io/api/news?id=6888c2c54723bb04edb3c5d67e07b46808bd427cf6affceefa0528189bbdc1be",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765284326,
      "headline": "Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack",
      "id": 137748347,
      "image": "https://image.cnbcfm.com/api/v1/image/108239182-17653017931765301790-42902890008-1080pnbcnews.jpg?v=1765301792&w=1920&h=1080",
      "related": "INCY",
      "source": "CNBC",
      "summary": "The Investment Committee debate the latest Calls of the Day.",
      "url": "https://finnhub.io/api/news?id=6888c2c54723bb04edb3c5d67e07b46808bd427cf6affceefa0528189bbdc1be"
    }
  },
  {
    "ts": null,
    "headline": "Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap?",
    "summary": "If you are wondering whether Incyte at around $96.70 is still a smart buy after its big run, you are in the right place to dig into what the market might be getting right or wrong about its value. Despite being down 5.2% over the last week and 8.8% over the last month, the stock is still up 39.1% year to date and 34.1% over the past year, which tells you sentiment has shifted meaningfully in its favor. Recent headlines around Incyte have focused on its expanding dermatology and oncology...",
    "url": "https://finnhub.io/api/news?id=4b5c7b915da332fc6244e8c3db07e700a8c43f0262ae41850f7193485f8bf8be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765260296,
      "headline": "Is Incyte Still Attractive After Its Strong 2025 Rally and DCF Valuation Gap?",
      "id": 137738217,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "If you are wondering whether Incyte at around $96.70 is still a smart buy after its big run, you are in the right place to dig into what the market might be getting right or wrong about its value. Despite being down 5.2% over the last week and 8.8% over the last month, the stock is still up 39.1% year to date and 34.1% over the past year, which tells you sentiment has shifted meaningfully in its favor. Recent headlines around Incyte have focused on its expanding dermatology and oncology...",
      "url": "https://finnhub.io/api/news?id=4b5c7b915da332fc6244e8c3db07e700a8c43f0262ae41850f7193485f8bf8be"
    }
  },
  {
    "ts": null,
    "headline": "Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower?",
    "summary": "Incyte recently reported encouraging Phase 1 data for its mutant-CALR antibody INCA033989 in myeloproliferative neoplasms and received a U.S. FDA Breakthrough Therapy designation for essential thrombocythemia, while also naming experienced life sciences lawyer Richard Hoffman as Executive Vice President and General Counsel to lead its legal and compliance functions. Together, the promising early data, expedited regulatory status and leadership change highlight how Incyte is pairing pipeline...",
    "url": "https://finnhub.io/api/news?id=50131795a4cd67e3ea450ad8919f67a73881ea547e2b1c99c151b8e02679ccf0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765246371,
      "headline": "Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower?",
      "id": 137738218,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte recently reported encouraging Phase 1 data for its mutant-CALR antibody INCA033989 in myeloproliferative neoplasms and received a U.S. FDA Breakthrough Therapy designation for essential thrombocythemia, while also naming experienced life sciences lawyer Richard Hoffman as Executive Vice President and General Counsel to lead its legal and compliance functions. Together, the promising early data, expedited regulatory status and leadership change highlight how Incyte is pairing pipeline...",
      "url": "https://finnhub.io/api/news?id=50131795a4cd67e3ea450ad8919f67a73881ea547e2b1c99c151b8e02679ccf0"
    }
  }
]